CN103239590A - 一种中药组合物及其制剂和用途 - Google Patents
一种中药组合物及其制剂和用途 Download PDFInfo
- Publication number
- CN103239590A CN103239590A CN2013101420405A CN201310142040A CN103239590A CN 103239590 A CN103239590 A CN 103239590A CN 2013101420405 A CN2013101420405 A CN 2013101420405A CN 201310142040 A CN201310142040 A CN 201310142040A CN 103239590 A CN103239590 A CN 103239590A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parts
- preparation
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 39
- 239000008187 granular material Substances 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 241000725145 Homalomena Species 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 239000000706 filtrate Substances 0.000 claims description 29
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 12
- 229940013618 stevioside Drugs 0.000 claims description 12
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 12
- 235000019202 steviosides Nutrition 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 11
- 235000019425 dextrin Nutrition 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 229920003091 Methocel™ Polymers 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- -1 hydroxypropyl Chemical group 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 241001446509 Psoralea Species 0.000 claims description 2
- 241001165494 Rhodiola Species 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229940109275 cyclamate Drugs 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001866 silicon dioxide Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 229940124583 pain medication Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 241001116742 Drynaria Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 43
- 210000000988 bone and bone Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 15
- 102000004067 Osteocalcin Human genes 0.000 description 14
- 108090000573 Osteocalcin Proteins 0.000 description 14
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 10
- 229960003957 dexamethasone Drugs 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000001672 ovary Anatomy 0.000 description 9
- 102000055006 Calcitonin Human genes 0.000 description 8
- 108060001064 Calcitonin Proteins 0.000 description 8
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 8
- 229960004015 calcitonin Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 210000002303 tibia Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 4
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 3
- 229940052490 naringin Drugs 0.000 description 3
- 229930019673 naringin Natural products 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010010582 Congenital osteodystrophy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007652 Dysostoses Diseases 0.000 description 1
- 201000001324 Dysostosis Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241001016310 Epimedium grandiflorum Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- KRTSDMXIXPKRQR-AATRIKPKSA-N monocrotophos Chemical compound CNC(=O)\C=C(/C)OP(=O)(OC)OC KRTSDMXIXPKRQR-AATRIKPKSA-N 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013101420405A CN103239590A (zh) | 2013-04-23 | 2013-04-23 | 一种中药组合物及其制剂和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013101420405A CN103239590A (zh) | 2013-04-23 | 2013-04-23 | 一种中药组合物及其制剂和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103239590A true CN103239590A (zh) | 2013-08-14 |
Family
ID=48919693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013101420405A Pending CN103239590A (zh) | 2013-04-23 | 2013-04-23 | 一种中药组合物及其制剂和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103239590A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104398697A (zh) * | 2014-11-06 | 2015-03-11 | 成都果睿医药科技有限公司 | 治疗骨质疏松的药物组合物 |
CN104606442A (zh) * | 2015-03-04 | 2015-05-13 | 陈红 | 一种治疗肾精亏虚型绝经后骨质疏松症的中药组合物 |
CN104825733A (zh) * | 2015-05-10 | 2015-08-12 | 王云花 | 一种用于治疗绝经后骨质疏松症的药物 |
CN105641188A (zh) * | 2016-01-08 | 2016-06-08 | 浙江中医药大学附属第三医院 | 益骨口服液、益骨的化合物单体以及口服液的医药应用 |
CN105796653A (zh) * | 2015-10-12 | 2016-07-27 | 烟台市蓝洋之草医药生物科技有限公司 | 一种治疗骨质疏松的药物组合物 |
CN107812067A (zh) * | 2017-12-18 | 2018-03-20 | 四川美大康药业股份有限公司 | 一种止痛壮骨胶囊的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101757372A (zh) * | 2009-10-20 | 2010-06-30 | 苏州派腾生物医药科技有限公司 | 一种治疗骨质疏松症的组合物及其制备方法 |
CN102824504A (zh) * | 2012-08-29 | 2012-12-19 | 赵秀兰 | 一种补肾壮骨的中药组合物 |
-
2013
- 2013-04-23 CN CN2013101420405A patent/CN103239590A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101757372A (zh) * | 2009-10-20 | 2010-06-30 | 苏州派腾生物医药科技有限公司 | 一种治疗骨质疏松症的组合物及其制备方法 |
CN102824504A (zh) * | 2012-08-29 | 2012-12-19 | 赵秀兰 | 一种补肾壮骨的中药组合物 |
Non-Patent Citations (3)
Title |
---|
李春生: "治疗骨质疏松症中药近10年研究进展", 《医学研究杂志》 * |
李茵等: "治疗骨质疏松症中药复方的数据挖掘", 《成都中医药大学学报》 * |
邓敦等: "复方中药治疗原发性骨质疏松的实验研究进展", 《中国中医骨伤科杂志》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104398697A (zh) * | 2014-11-06 | 2015-03-11 | 成都果睿医药科技有限公司 | 治疗骨质疏松的药物组合物 |
CN104606442A (zh) * | 2015-03-04 | 2015-05-13 | 陈红 | 一种治疗肾精亏虚型绝经后骨质疏松症的中药组合物 |
CN104825733A (zh) * | 2015-05-10 | 2015-08-12 | 王云花 | 一种用于治疗绝经后骨质疏松症的药物 |
CN105796653A (zh) * | 2015-10-12 | 2016-07-27 | 烟台市蓝洋之草医药生物科技有限公司 | 一种治疗骨质疏松的药物组合物 |
CN105641188A (zh) * | 2016-01-08 | 2016-06-08 | 浙江中医药大学附属第三医院 | 益骨口服液、益骨的化合物单体以及口服液的医药应用 |
CN105641188B (zh) * | 2016-01-08 | 2019-10-08 | 浙江中医药大学附属第三医院 | 益骨口服液、益骨的化合物单体以及口服液的医药应用 |
CN107812067A (zh) * | 2017-12-18 | 2018-03-20 | 四川美大康药业股份有限公司 | 一种止痛壮骨胶囊的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101584797B (zh) | 一种中药组合物在制备治疗更年期综合征的药物中的应用 | |
CN103239590A (zh) | 一种中药组合物及其制剂和用途 | |
CN105663607B (zh) | 一种中药组合物及其制备方法和用途 | |
CN101773561B (zh) | 一种具有补肾、活血、止痛的中药组合物及其制备方法 | |
CN101138597B (zh) | 一种防治骨质疏松症的中药制剂及其制备方法 | |
CN102526444A (zh) | 一种补肾壮阳的中药组合物及其制备方法 | |
CN102048890A (zh) | 一种具有催乳作用的中药组合物及其制备方法 | |
CN102048841A (zh) | 一种具有催乳作用的中药组合物及其制备工艺 | |
CN113876834B (zh) | 一种中药提取物在制备抗乳腺增生中药产品中的用途 | |
CN104324316A (zh) | 一种中药组合物在制备治疗大肠癌药物中的应用 | |
CN102225155B (zh) | 一种治疗肺纤维化的药物组合物 | |
CN100428952C (zh) | 一种治疗更年期综合症的药物及其制备方法 | |
CN102813873A (zh) | 治疗精神疾病中药组合物及其制备方法、用途和质量控制 | |
CN106421630A (zh) | 一种郁金提取物及其制备方法和应用 | |
CN101543574A (zh) | 一种治疗肺间质纤维化的中药组合物 | |
CN100409892C (zh) | 一种用于治疗乳腺增生的外用药及其制备方法 | |
CN107865932B (zh) | 一种具有减肥功效的中药组合物 | |
CN104173521B (zh) | 一种生精壮阳的药物组合物及其制备方法 | |
CN1965951A (zh) | 驴胶补血胶囊及制备方法 | |
CN112386671B (zh) | 一种治疗间质性肺疾病的中药组合物及其应用 | |
CN101244127B (zh) | 用于治疗血管性痴呆症的药物 | |
CN108210873B (zh) | 一种增加雌激素的中药组合物及其应用 | |
CN101879227B (zh) | 一种治疗腰椎间盘突出症的中药组合物及其制备方法 | |
CN109045240B (zh) | 一种更辰制剂的中药组合物、其制备方法和检测方法及应用 | |
CN101468124A (zh) | 一种防治月经不调的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 225441, Baota Road, Daqing West Road, Taixing, Jiangsu, Taizhou Applicant after: Jumpcan Pharmaceutical Group Co., Ltd. Address before: 225441 Jiangsu, Taizhou, Taixing, Daqing West Road, pagoda Bay, Sichuan Pharmaceutical Group, Limited by Share Ltd Applicant before: Jiangsu JumpCan Medicines Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: JIANGSU JUMPCAN MEDICINES CO., LTD. TO: JUMPCAN PHARMACEUTICAL GROUP CO., LTD. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 225441, Baota Road, Daqing West Road, Taixing, Jiangsu, Taizhou Applicant after: Jumpcan Pharmaceutical Group Co., Ltd. Address before: 225441, Baota Road, Daqing West Road, Taixing, Jiangsu, Taizhou Applicant before: Jumpcan Pharmaceutical Group Co., Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130814 |